Study to Create a Database of Digital and Blood Biomarkers and Their Link to Tau and Amyloid PET Imaging in Older Adults With Normal Cognition, Mild Cognitive Impairment, or Mild-to-Moderate Alzheimers Disease Dementia

What this Trial Is About

Researchers are developing a database to study digital and blood-based biomarkers and their relationship with tau and amyloid brain pathology detected by PET imaging in older adults. The study includes participants who are cognitively normal, have mild cognitive impairment, or have mild-to-moderate Alzheimers disease dementia. The goal is to understand how these biomarkers relate to brain changes associated with Alzheimers disease and memory disorders. Participants will provide blood samples and undergo brain imaging, including PET scans using either an FDA-approved tracer or an investigational one, as well as MRI scans. Genetic samples will also be collected to explore genetic factors related to Alzheimers disease and treatment responses. Some samples will be stored for future research. The study lasts 120 days and includes a cross-sectional assessment. Throughout the study, participants will undergo blood sampling, PET scans, MRI scans, and cognitive testing, including the Mini-Mental State Exam. Researchers will track biomarkers and imaging results over an average of three years. Participants will also have study partners who provide information about their cognitive and functional abilities. The study collects comprehensive data to better understand Alzheimers disease and related conditions in older adults.

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia